Ovid Therapeutics to Participate in the JMP Securities 2017 Life Sciences Conference

NEW YORK, June 12, 2017 -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines for patients with rare neurological disorders, today announced that Yaron Werber, MD, chief business and financial officer of Ovid, will participate in the upcoming JMP Securities 2017 Life Sciences Conference.

Dr. Werber will participate in a panel discussion entitled “The Emerging Landscape of Orphan / CNS Disorders” on Tuesday, June 20, 2017 at 1:00 p.m. EDT. The conference will be held at the St. Regis Hotel in New York, NY.

About Ovid Therapeutics
Ovid Therapeutics (NASDAQ:OVID) is a New York-based, biopharmaceutical company using its BoldMedicine^TM approach to develop therapies that transform the lives of patients with rare neurological disorders. Ovid’s drug candidate, OV101, is currently in development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman syndrome or Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid expects to initiate a Phase 1b/2a trial of OV935 to treat rare epileptic encephalopathies in 2017.

For more information on Ovid, please visit http://www.ovidrx.com/.

Ovid Contacts:
Investors:
Burns McClellan
Steve Klass, 212-213-0006
[email protected]

Media:
Pure Communications, Inc.
Katie Engleman, 910-509-3977
[email protected]